Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.

Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI.

Eur J Clin Pharmacol. 2013 Mar;69(3):589-98. doi: 10.1007/s00228-012-1344-0. Epub 2012 Jul 19.

PMID:
22811260
2.

The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective.

Pottegård A, Bjerregaard BK, Glintborg D, Hallas J, Moreno SI.

Eur J Clin Pharmacol. 2012 Oct;68(10):1443-50. doi: 10.1007/s00228-012-1265-y. Epub 2012 Mar 21.

PMID:
22434389
3.

Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.

Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S.

Curr Med Res Opin. 2010 Apr;26(4):977-89. doi: 10.1185/03007991003673617.

PMID:
20178404
4.

Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009.

Zetterqvist J, Asherson P, Halldner L, Långström N, Larsson H.

Acta Psychiatr Scand. 2013 Jul;128(1):70-7. doi: 10.1111/acps.12004. Epub 2012 Sep 4.

PMID:
22943458
5.
6.

Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.

Janols LO, Liliemark J, Klintberg K, von Knorring AL.

Nord J Psychiatry. 2009 Nov;63(6):508-16. doi: 10.3109/08039480903154534.

PMID:
19958258
7.

Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish nationwide drug utilization study.

Pottegård A, Bjerregaard BK, Kortegaard LS, Zoëga H.

Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):349-53. doi: 10.1111/bcpt.12325. Epub 2014 Oct 7.

8.

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.

Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.

Ann Pharmacother. 2008 Jan;42(1):24-31. Epub 2007 Nov 27.

PMID:
18042808
9.

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E.

Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490.

10.

Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.

Treceño C, Martín Arias LH, Sáinz M, Salado I, García Ortega P, Velasco V, Jimeno N, Escudero A, Velasco A, Carvajal A.

Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):435-41. doi: 10.1002/pds.2348. Epub 2012 Jan 17.

PMID:
22253017
11.

Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.

Furu K, Karlstad Ø, Zoega H, Martikainen JE, Bahmanyar S, Kieler H, Pottegård A.

Basic Clin Pharmacol Toxicol. 2017 Apr;120(4):373-379. doi: 10.1111/bcpt.12724. Epub 2017 Jan 30.

PMID:
27911044
12.

Prescriptions for ADHD medication, 2004-08.

Lillemoen PK, Kjosavik SR, Hunskår S, Ruths S.

Tidsskr Nor Laegeforen. 2012 Sep 4;132(16):1856-60. English, Norwegian.

13.

A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Rösler M, Fischer R, Ammer R, Ose C, Retz W.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.

PMID:
19165529
14.

A nationwide study of attention-deficit/hyperactivity disorder drug use among adults in Iceland 2003-2012.

Geirs DP, Pottegård A, Halldórsson M, Zoëga H.

Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):417-22. doi: 10.1111/bcpt.12243. Epub 2014 May 6.

15.

Trends of outpatient prescription drug utilization in US children, 2002-2010.

Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D.

Pediatrics. 2012 Jul;130(1):23-31. doi: 10.1542/peds.2011-2879. Epub 2012 Jun 18.

PMID:
22711728
16.

ADHD medication use, adherence, persistence and cost among Texas Medicaid children.

Barner JC, Khoza S, Oladapo A.

Curr Med Res Opin. 2011;27 Suppl 2:13-22. doi: 10.1185/03007995.2011.603303.

PMID:
21973228
18.

Trends in the prescribing of stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder in adults in New South Wales.

New South Wales Department of Health.

N S W Public Health Bull. 2004;15 Suppl 3:1-55. No abstract available.

PMID:
15448720
19.

Predictors and impact of non-adherence in adults with attention-deficit/hyperactivity disorder receiving OROS methylphenidate: results from a randomized, placebo-controlled trial.

Kooij JJ, Rösler M, Philipsen A, Wächter S, Dejonckheere J, van der Kolk A, van Agthoven M, Schäuble B.

BMC Psychiatry. 2013 Jan 24;13:36. doi: 10.1186/1471-244X-13-36.

20.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731

Supplemental Content

Support Center